- Home
- UHT vs IMAB Comparison
UHT vs IMAB Comparison
Compare UHT & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UHT
- IMAB
- Stock Information
- Founded
- UHT 1986
- IMAB 2014
- Country
- UHT United States
- IMAB United States
- Employees
- UHT N/A
- IMAB N/A
- Industry
- UHT Real Estate Investment Trusts
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- UHT Real Estate
- IMAB Health Care
- Exchange
- UHT Nasdaq
- IMAB Nasdaq
- Market Cap
- UHT 515.7M
- IMAB 486.4M
- IPO Year
- UHT N/A
- IMAB 2020
- Fundamental
- Price
- UHT $37.20
- IMAB $4.64
- Analyst Decision
- UHT
- IMAB Strong Buy
- Analyst Count
- UHT 0
- IMAB 6
- Target Price
- UHT N/A
- IMAB $7.50
- AVG Volume (30 Days)
- UHT 76.5K
- IMAB 2.2M
- Earning Date
- UHT 10-27-2025
- IMAB 11-14-2025
- Dividend Yield
- UHT 7.96%
- IMAB N/A
- EPS Growth
- UHT N/A
- IMAB N/A
- EPS
- UHT 1.30
- IMAB N/A
- Revenue
- UHT $100,639,000.00
- IMAB N/A
- Revenue This Year
- UHT N/A
- IMAB N/A
- Revenue Next Year
- UHT $0.81
- IMAB N/A
- P/E Ratio
- UHT $28.06
- IMAB N/A
- Revenue Growth
- UHT 0.74
- IMAB N/A
- 52 Week Low
- UHT $34.56
- IMAB $0.60
- 52 Week High
- UHT $43.38
- IMAB $6.79
- Technical
- Relative Strength Index (RSI)
- UHT 47.31
- IMAB 48.87
- Support Level
- UHT $36.04
- IMAB $4.13
- Resistance Level
- UHT $37.16
- IMAB $6.79
- Average True Range (ATR)
- UHT 0.83
- IMAB 0.67
- MACD
- UHT 0.17
- IMAB -0.14
- Stochastic Oscillator
- UHT 85.27
- IMAB 19.17
About UHT Universal Health Realty Income Trust
Universal Health Realty Income Trust is a healthcare REIT. The company is engaged in the business of investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. The company actively manages a portfolio of healthcare and human service facilities. The revenue and net income are generated from the operation of the investment portfolio, located throughout the United States.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).